

Curriculum Vitae

Richard A. Linforth
Consultant Breast Surgeon
MD. FRCS (ENG), (ED), FRCS (Gen Surg)

1. 12. 2019

ricklinforth@yorkshirebreastclinic.com

Name: Richard Anthony Linforth.

Nationality: British.

Qualifications: M.B.C.h.B. Manchester University July 1992.
F.R.C.S. (ED) Edinburgh Royal College of Surgeons Feb 1997.
M.D. Manchester University Oct 2005
FRCS (Gen Surg) Intercollegiate Colleges of Surgeons April 2006
FRCS (ENG) Royal college of Surgeons England Feb 2017

Current positions: **Consultant Onco-Plastic Breast Surgeon** 2006-
Bradford Teaching Hospitals Foundation Trust
National Oncoplastic Trainer for the Association of Breast Surgeons
Great Britain and Ireland (ABSGBI).

Previous positions held **Divisional Clinical Director All Surgery and Anaesthesia** 2013-16

Responsible officer for the provision of all Surgery and Anaesthesia
including critical care, theatres, and all surgical specialities.

**Clinical Director for Breast, Plastics, Maxillo-facial
and Oral Surgery.** 2011-13

Clinical Lead Bradford Breast Unit 2009-13
Chair of Breast Cancer Multidisciplinary Team 2009-12

Breast MDT lead 2009-11

MD Thesis: The Role of PTHrP and receptor in breast cancer and metastases
Award of MD October 2005. Manchester University.

Professional Bodies

Association of Breast Surgeons Great Britain and Ireland 101655
American Society of Breast Surgeons 12152
Fellow Royal College of Surgeons of England 1007043
Fellow Royal College of Surgeons of Edinburgh 23265
Medical Defence Union. 261677A
General Medical Council. 3585834

Experience

Divisional Clinical Director of Surgery and Anesthesia. 2013-2016

I was responsible for the Strategic management of over 1400 staff with a budget of £90million, driving patient safety, quality and clinical governance along with human resources, research and innovation. I was supported by a team of Clinical Directors (5), Directorate Managers (5) and Matrons (7), along with a Medical Specialty lead for each Surgical and Anesthetic discipline.

I was performance managed against achieving the NHS standards including 18week Referral to Treatment (RTT), 2 week fast track cancer targets, 31 and 62 day first treatments, infection control and Patient Quality and Safety standards.

I was also responsible for Medical mandatory training, appraisal, service development and financial balance. I had annual Quality improvement target of £5 million for the Division.

I reported directly to the Chief Operating Office and Medical Director along with the Executive Directors of the trust. This post was for 7 sessions per week, with 6 additional breast clinical sessions per week. At the end of this three-year post I returned to full time breast practice. During this period, I received 3 CQC inspections and the division was rated green good. I received two Clinical Excellence awards.

Clinical director of Breast, Plastic, Maxillo-Facial and Dental Surgery 2011-2013

Following a successful two years as the Clinical lead for Breast Surgery and the Calman Cancer MDT lead for Breast I was appointed as Clinical Director of Surgical specialties which deals with a wide range of challenging cancers treated with reconstructive Onco-plastic Surgery.

I managed a team of 12 Consultant reconstructive surgeons across three major surgical disciplines, along with over 40 junior medical staff and 60 nurses and support staff.

I had the support of the Consultant leads for each of the three specialities, with the aim of bring the National Cancer Peer review process up to the high standards achieved in my own discipline of breast surgery, which was the highest in the Yorkshire Deanery.

During my time, as Clinical Lead in Breast Surgery I achieved three Clinical Excellence awards for my achievements in turning around a struggling breast unit, into a National Onco-plastic Training centre, at the forefront of innovative technologies.

Doctorate of Medicine (M.D.) Award

I was the holder of the Professor Tom Jones research fellowship from the University of Manchester. This award was made following the acceptance of my research proposals, which led to the submission and award of the degree of Doctor of Medicine (MD).

Under Professor Nigel Bundred, Professor of Surgical Oncology/ Consultant Surgeon and Dr Neil Anderson PhD I investigated the role of Parathyroid hormone related protein and its receptor in breast cancer. I studied the expression of oncogenes implicated in breast cancer including the then novel oncogenes of Her 2, EGFR, PTHrP, PTHrP receptor, MAP Kinases and Others.

I took part in multidisciplinary clinics with Professor Gareth Evans Consultant in Genetics for women at high risk of breast cancer involving counselling for genetic testing (BRCA1 and 2), risk reduction surgery and surveillance.

I also co-ordinated a phase three clinical trial of Ibandronate versus pamidronate for hypercalcaemia and was involved in both the ATAC trial (Astrazeneca) and Exemestane trials (Pharmacia & Upjohn) of adjuvant endocrine therapy.

National Oncoplastic Fellowship Award 20004

The Association of Breast Surgeons (ABS) with the British Association of Plastic Surgeons (BAPS) successfully petitioned the Department of Health to fund nine one-year training posts for the purpose of creating more Breast Reconstructive Surgeons. The National posts are funded centrally and meet the requirements of the SAC in both General and Plastic Surgery.

I was successfully appointed as the National Oncoplastic Fellow for Manchester commencing Oct 2004 for one year. The lead Surgeons were Prof Andrew D Baildam and Miss Anne Brain.

During this year I gained skills in both breast oncological techniques such as sentinel node biopsy and therapeutic mammoplasty (wide local excision with reshaping of the breast to avoid cavity defects), along with plastic reconstructive techniques including tissue expander/Implant reconstruction, Latissimus dorsi myocutaneous pedicled reconstruction, breast reduction and symmetrisation techniques, breast augmentation and nipple areolar reconstruction and tattooing. I also had the opportunity to take part in free flap breast reconstruction using the Trans rectus abdominis muscle (TRAM) technique and DIEP flaps.

The Mammary fold-The National Breast Trainees Group 2004-2006

In 2004 with Stephen Thrush and Iain Brown I formed The Mammary fold -The National Breast Surgeon Trainees Group. This is the largest trainee group in the world and is now completely integrated in the Association of Breast Surgeons of Great Britain and Ireland.

In May of 2005 I was elected as President, following my previous appointment as Education and training representative. Our Group had a membership of 300 trainees and representation on National councils such as the ABS Executive Committee, ABS Education and training sub-committee and BIG 18 group. I have, along with the past Chair and Secretary organised successful National meetings and study days at the ABS National meeting in Birmingham with speakers including John Black (Chairman of the SAC) and Fiona MacNeil (RCS England Breast tutor), Oncoplastic Training Meeting Nottingham Sept 2005- 200 delegates speakers including Dick Rainsbury, Douglas MacMillan and Steve McCulley. With Sponsorship from AstraZeneca we ventured to Europe with an all expenses paid meeting in Barcelona for 30 delegates and five invited speakers. In addition, our National meeting took place at Nottingham in parallel with the ABS meeting in June 2006 funded from national pharmaceutical companies. I was involved in writing a new curriculum for breast trainees and the petitioning of ABS members regarding a new SAC in breast surgery. This group has now been adopted and supported by the Association of Breast Surgeons.

Medico-Legal Practice 2014-date

I have a medico-legal practice writing Expert witness reports for the court. I receive 30-40 instructions per year, with a 60/40 split defence/claimant.

To support this work, I have attended the Medico-legal Expert training 2015 in York provided by Jonathan Dingle FRSA and Judith Kelbie LLP.

I have completed the 5-day Bond Solon Expert Witness Course (September 18-February 2019). and have applied for the Cardiff University Bond solon certificate.

I have also completed the National Mortality Case Record Review course at the trust, using the Royal College of Physicians Structured Judgement review methodology.

I have received instruction from Bev Brittan LLP, DAC Beechcroft LLP, Mellor Hargreaves LLP, TMLEP and several individual Solicitors.

I have attended Civil court once, Criminal court once and Coroners court once
I have also served as a juror.

I attended the Bond Solon Expert Witness Conference Nov 2019.

Papers published in Peer reviewed Journals

1.

Co-expression of Parathyroid Hormone Related Protein and its Receptor in Early Breast Cancer Predicts Poor Patient Survival

Richard Linforth, Neil Anderson, Richard Hoey, Tania Nolan*, Sarah Downey, Gerard Brady*, Linda Ashcroft, and Nigel Bundred

Clinical Cancer Research October 2002 :8;3172-3177 Journal of the AACR.

2.

The Role of Mastectomy in the Management of Breast Cancer.

Richard Linforth and Nigel Bundred

For the European School of Oncology Advanced Education Series Breast Cancer, Diagnosis and Management Editor Mike J Dixon. 1999.

3.

Breast Lumps and cancer

InnovAiT **2009** 2(1):17-23; doi:10.1093/innovait/inn150 **Rick Linforth**

GP registrars Journal.

4.

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

Rowan Chlebowski, Jack Cuzick, Dereck Amakye, Ingo Bauerfeind, Aman Buzdar, Stephen Chia, Bruno Cutuli, **Rick Linforth**, Nicolaì Maass, Shinzaburo Noguchi, André Robidoux, Sunil Verma, Peyman Hadji pages S1-S11 The breast Volume 18, Supplement 2 (**August 2009**)

An International gathering of invited world opinion leaders.

5.

Mammographic surveillance in women aged 35–39 at enhanced familial risk of breast cancer (FH02)

Authors: D Gareth Evans, A. Howell, S. Thomas, J. Caunt, L. Roberts, M. Wilson, R. Fox, D. M. Sibbering, S. Moss, M. G. Wallis, D. M. Eccles, S. Duffy, Eleanor Waldron, Lesley Smart, Lynda Luke, Simerjit Rai, Richard Linforth, et al .

Familial Cancer, Vol. 13, No. 1, 03.2014, p. 13-21

6.

Identification of stage-specific breast markers using quantitative proteomics.

Shaheed SU, Rustogi N, Scally A, Wilson J, Thygesen H, Loizidou MA, Hadjisavvas A, Hanby A, Speirs V, Loadman P, Linforth R, Kyriacou K, Sutton CW.

J Proteome Res. 2013 Dec 6;12(12):5696-708. doi: 10.1021/pr400662k. Epub 2013 Oct 29.

7.

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; et al IBIS-II investigators.

Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
Erratum in: Lancet. 2014 Mar 22;383(9922):1040.
PMID: 24333009 Free Article

8.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, et al IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
PMID: 26686313 Free PMC Article

9.

Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.

Glassman D, Hignett S, Rehman S, Linforth R, Salhab M.

Anticancer Res. 2017 Oct;37(10):5329-5341. Review.

10.

Variation in the provision and practice of implant-based breast reconstruction in the UK: Results from the iBRA national practice questionnaire.

Mylvaganam S, Conroy E, Williamson PR, Barnes NLP, Cutress RI et al iBRA Steering Group; Breast Reconstruction Research Collaborative.

Breast. 2017 Oct; 35:182-190. doi: 10.1016/j.breast.2017.07.016. Epub 2017 Jul 30.

PMID: 28768227 Free PMC Article

11

Adherence to best practice consensus guidelines for implant-based breast reconstruction: Results from the iBRA national practice questionnaire survey.

Mylvaganam S, Conroy EJ, Williamson PR, Barnes NLP, Cutress RI, et al iBRA Steering Group; Breast Reconstruction Research Collaborative.

Eur J Surg Oncol. 2018 Feb 7. pii: S0748-7983(18)30135-5. doi: 10.1016/j.ejso.2018.01.098.

12.

Aspirin and ibuprofen, in bulk and nanofoms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals.

Dandah O, Najafzadeh M, Isreb M, Linforth R, Tait C, Baumgartner A, Anderson D.

Mutat Res. 2018 Feb;826:41-46. doi: 10.1016/j.mrgentox.2017.12.001. Epub 2017 Dec 24.

13.

Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.

Shaheed SU, Tait C, Kyriacou K, Linforth R, Salhab M, Sutton C.

Clin Proteomics. 2018 Jan 11;15:3. doi: 10.1186/s12014-017-9179-4. eCollection 2018. Review.

14

Nipple aspirate fluid-A liquid biopsy for diagnosing breast health.

Shaheed SU, Tait C, Kyriacou K, Mullarkey J, Burrill W, Patterson LH, Linforth R, Salhab M, Sutton CW.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201700015. Epub 2017 Jun 26.

PMID: 28488344 Free PMC Article

15.

Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35–39 at Increased Familial Risk of Breast Cancer☆ D.G. Evans a,b,c, *, S. Thomas e, J. Caunt e, A. Burch e, A.R. Brentnall g, L. Roberts a, A. Howell a,c, M. Wilson d, R. Fox e, S. Hillier e, D.M. Sibbering f, S. Moss g, M.G. Wallis h, D.M. Eccles i, FH02 study group, S. Duffy et al (Linforth R)

E Clinical Medicine, Vol. 7, p39–46 Published: February 10, 2019

16.

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study.

O'Connell RL, Rattay T, Dave RV, Trickey A, Skillman J, Barnes NLP, Gardiner M, Harnett A, Potter S, Holcombe C; iBRA-2 Steering Group; **Breast Reconstruction Research Collaborative.**

Br J Cancer. 2019 Apr;120(9):883-895. doi: 10.1038/s41416-019-0438-1. Epub 2019 Mar 29.

17.

Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study.

Potter S, Conroy EJ, Cutress RI, Williamson PR, Whisker L, Thrush S, Skillman J, Barnes NLP, Mylvaganam S, Teasdale E, Jain A, Gardiner MD, Blazeby JM, Holcombe C; iBRA Steering Group; **Breast Reconstruction Research Collaborative.**

Lancet Oncol. 2019 Feb;20(2):254-266. doi: 10.1016/S1470-2045(18)30781-2. Epub 2019 Jan 9.

Oral Abstract Presentations and Publications to learned societies.

1. Parathyroid Hormone related Protein Receptor Expression in Breast cancer and Bone metastases.

Linforth R.A., Hoey RP, Nolan T, Brady G, Anderson N, and Bundred N.

Presented at the **2nd International conference of Cancer Induced Bone disease, March 27th-29, 1999 Davos** Switzerland, and abstract **published on Osteovision** <<http://WWW.osteovision.ch>>

2. The Expression of PTHrP and its receptor in bone metastases from prostate cancer.

Iddon J, **Linforth R.A.**, Downey SE, Freemont A, and Bundred N.

Presented at the **2nd International conference of Cancer Induced Bone disease, March 27th-29, 1999 Davos** Switzerland, and abstract **published on Osteovision** <<http://WWW.osteovision.ch>>

3. Early breast cancers expressing oestrogen receptors over express the Parathyroid Hormone related Protein (PTHrP) Receptor.

Linforth R.A., Hoey RP, Nolan T, Brady G, Anderson N, and Bundred N

Presented to the **6th Nottingham International Breast Cancer Conference, Sept 22-24 1999**

4. Over expression of Parathyroid Hormone related Protein (PTHrP) Receptor in breast cancer bone metastases.

Linforth R.A., Hoey RP, Nolan T, Brady G, Anderson N, and Bundred N.

Presentation at the **2nd North American Symposium on Skeletal complications of Malignancy. Oct 15-16**

and poster at the **22nd annual San Antonio symposium of breast cancer. Dec 7-11th 1999.**

Published: Breast Cancer Results and Treatment supplement.vol 57, no1. 1999.

5. Peri-operative Magnetic Resonance Imaging in Early Breast Cancer.

Linforth R.A., Iddon. J, Wilson.M, Baildem.A, and Bundred N.

Presented to the **2nd North American Symposium on Skeletal complications of Malignancy. Oct 15-16 1999.**

Published: Cancer supplement June 15, 2000:88:12 p3092.

6.Genetic Profiling of Breast Tumours

T.Nolan, **R.A.Linforth**, N.Bundred, N.Anderson, P.Hedge and G.Brady.

Presented at **Genes and Cancer 1999, 13-15 December, Warwick University,UK.**

7. Parathyroid Hormone related Protein (PTHrP) and Receptor co-expression in breast cancer and bone metastases.

Linforth R.A., Nolan T, Downey S, Brady G, Anderson N, and Bundred N

Presented to the **SRS in the Patey Prize session, Millennium meeting, Cardiff 23-26 May 2000.**

Published: BJS vol 87 supplement1 pg14.

8. Incidence of residual breast epithelium following Mastectomy

Linforth R.A., Iddon J, F.Knox,A.D.Baildam and Bundred N

Presented to the **ASGBI Millennium meeting, Cardiff 23-26 May 2000.**

Published: BJS vol 87 supplement1 pg59.

9. Cigarette smoking is an aetiological factor in Hidradenitis Suppurativa

Linforth R.A., Morris J and Bundred N

Presented to the **ASGBI Millennium meeting, Cardiff 23-26 May 2000.**

Published: BJS vol 87 supplement1 pg34.

10. Characterization of mitogenic actions of Parathyroid hormone-related protein in MCF-7 breast carcinoma cells

Anderson N, Hoey R, **Linforth R.A** and Bundred NJ

Presented to the **SRS, Millennium meeting, Cardiff 23-26 May 2000.**

Published: BJS vol 87 supplement1 pg26.

11. Serum VEGF and VCAM, value as markers of angiogenesis and metastasis in breast cancer.

Elangahan E, Byrne G, **Linforth R.A.** and Bundred NJ.

Presented to the **SRS in the Patey Prize session, Millennium meeting, Cardiff 23-26 May 2000.**

Published: BJS vol 87 supplement1 pg2

12. Parathyroid Hormone related Protein (PTHrP) and Receptor co-expression predicts a poor prognosis in breast cancer.

Linforth R.A., Nolan T, Downey S, Brady G, Anderson N, and Bundred N

Presented to the **2nd European breast cancer conference, Brussels Sept 2000.**

13. Mitogenic actions of Parathyroid hormone-related protein in MCF-7 breast carcinoma cells
Anderson N, Hoey R, **Linforth R.A** and Bundred NJ.

Presented to the **23rd San Antonio Breast cancer conference, Dec 2000**

14. Early Breast Cancers (EBC) expressing Epidermal Growth Factor Receptor (EGFR) have increased parathyroid hormone related protein (PTHrP) expression.

R.A.Linforth*, N.G.Anderson, F.Knox and N.J.Bundred.

Presented to the SRS , Birmingham April, 2001 and **Published in the BJS supp**

15. Cerb2 oncoprotein expression is increased in breast cancer bone metastases.

R.A.Linforth*, N.G.Anderson, W.F.Knox and N.J.Bundred

Presented to the ASGBI, Birmingham April, 2001 and **Published in the BJS supp**

16 . ABBI: Definitive Surgical Treatment for Small Breast Cancers

A.K.Modi, TKMahapatra, **R.A.Linforth**, J.N.Fox,A.Hubbard and P.J.Drew

Presented to the 3rd Milan Breast Cancer Conference, June13-15 2001

To be Published in “The Breast” Journal.

17. ABBI: Excision of Benign Lesions leave Minimal mammographic scarring

A.K.Modi, **R.A.Linforth**, P.J.Drew, TKMahapatra, J.N.Fox, and A.Hubbard.

Presented to the 3rd Milan Breast Cancer Conference, June13-15 2001

Published in “The Breast” Journal.

18. Factors Predisposing Positive margins when ABBI is used as an excision tool for breast cancer

A.K.Modi, **R.A.Linforth**, P.J.Drew, TKMahapatra, J.N.Fox, and A.Hubbard.

Presented to the 3rd Milan Breast Cancer Conference, June13-15 2001
Published in “The Breast” Journal.

19. Infusional Neo-Adjuvant iFEC produces useful Tumour reduction

A.K.Modi, **R.A.Linforth**,S Upadhayay.and A.Chatervedi.

Presented to the 3rd Milan Breast Cancer Conference, June13-15 2001

Published in “The Breast” Journal.

20 Cerbb2 oncoprotein expression in breast cancer bone and visceral metastases.

R.A.Linforth*, N.G.Anderson, W.F.Knox and N.J.Bundred

Presented to the 8th Nottingham International Breast Cancer Conference. Sept 2001.

Published in the European Journal of Cancer.

21 Incidence of malignancy in indeterminate breast imaging.

Dalia Elfadl*, **Richard Linforth**, NK Jain, George Thomas, Narinder Sharma and Vijay Modgill.

Presented to the ASGBI Harrogate 2004 published in the BJS supplement.

22. The Impact of a Combined Breast Reconstruction Clinic-The Bradford Experience

Saleh DB, Williams AM, **Linforth RA**, Rhodes ND
Oncoplastic Reconstructive Breast Symposium (ORBS) Nottingham, UK 2008.

23. Skin sparing Mastectomy and Immediate Single Stage Implant based reconstruction using Acellular dermal Matrix strattice

Waterworth A, Tait CR, **Linforth RA**. Bradford Hospitals UK
16th World Congress of the Senological International Society and 29th National Congress of the Spanish Society of Senology and Breast disease. Valencia Spain Oct 21st 2010.

24. Cost-effectiveness of Single stage implant based reconstruction using Strattice

Waterworth A, Tait CR, **Linforth RA**. Bradford Hospitals UK
16th World Congress of the Senological International Society and 29th National Congress of the Spanish Society of Senology and Breast disease. Valencia Spain Oct 21st 2010.

25. First European Experience of Skin Sparing Mastectomy and Immediate Reconstruction Using Acellular Dermal Matrix Strattice and Implant.

Claire Murphy, A. Waterworth, N. Rhodes, **RA. Linforth**
Bradford Teaching Hospitals Foundation Trust, Department of Breast
Association of Breast Surgeons BJS Prize Papers, Manchester 2011 doi:10.1016/j.ejso.2011.03.001.
European Journal Of Surgery EJSO 37 (2011) S1-S3

26. Breast Needle Core Biopsy Diagnosis of Papillary Carcinoma - Implications of a B5c

Categorisation. M Singh, P Bennett, P Carder and **RA Linforth**.

Association of Breast Surgeons meeting, Manchester 2011
European Journal Of Surgery EJSO 37 (2011)

27. Audit of bilateral x-ray mammography in symptomatic patients aged 35-9: Is it safe to change

our unit's practice? Julia Massey, Cathy Tait, Anne-Marie Wason, **Richard Linforth**

EJSO Volume 38, Issue 5, May 2012, Pages 427-428

28. Radiological staging of symptomatic high risk breast cancer patients is of limited value.

Mohamed Salhab, Reem Elghazawy, Catherine Tait, **Richard Linforth**, 1 Breast Unit, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, UK 2013

EJSO <http://dx.doi.org/10.1016/j.ejso.2013.01.098>

29. Reducing margin width following breast conserving surgery increases risk of residual disease in

the breast: Brian Hogan, S Chan, M Salhab, **R Linforth**, C Tait.

EJSO November 2014 Volume 40, Issue 11, Page S80

30. The short-term safety profile of ARTIATM ADM implant based Immediate breast reconstruction.

Benjamin Wood, Catherine Tait (Associate Specialist Breast Surgery), **Richard Linforth**.

Nottingham Oncoplastic Breast Symposium (ORBS) 25th - 27th September 2017

Current Research:

I continue to work with the biotech companies and am an International advisor to Lifecell and who continue to develop matrix devices for breast reconstruction.

In the past I have also been an Advisor to AstraZeneca, Novartis, Bosom friends of Bradford and The Haven Trust breast cancer charity whose patron is HRH Prince Charles.

I have piloted the first acellular dermal matrix (ADM-Strattice) single stage implant based immediate breast reconstruction following mastectomy. The first European procedure was performed in Bradford by me in June 2008 and over 200 subsequent procedures performed to date. The early work was presented at the First International Onco-plastic reconstructive breast symposium (ORBS) in Nottingham in 2008, and more recently at the Association of Breast Surgeons meeting in Manchester 2011. I have now demonstrated this technique at the Bioskills Lab in Rotterdam to invited European and UK delegates and elsewhere around Europe and the UK to over 800 hundred surgeons. It has now become an established procedure in many UK hospitals and throughout the world

I am currently using Artia™ in a pre-pectoral direct to implant, which we presented in Nottingham in 2017, the first world publication on Short term safety and effectiveness.

Audit

I ensure participation in a number of local and National audits of the work I perform. These include:

The National Mastectomy and Reconstruction Audit Royal College of Surgeons (2009)

The ABS Sloan Project on DCIS (2009)

The ABS BCCOM project an audit of symptomatic breast cancers (2006 to date)

The use of Sentinel node biopsy in Bradford. First 100 cases (2006-2008)

B5c biopsies of the breast- pathological outcomes.(2011)

European Experience of Strattice implant reconstruction.(2008-to date)

IBRA- direct to implant reconstruction 2016-current.

All my work both NHS and Private is Peer reviewed through the Bradford MDT ensuring the highest quality and Safety. This is recorded in the Annual report which is published on the Cquins web site for all to see. I wrote the original operational policy for the Breast MDT which has been revised annual by the current MDT lead and Head of Nursing.

Recent Invited Speaker events

First Thoughts Breast Cancer Conference RCP London Jan 2015

Oncoplastic Reconstructive Breast Symposium Nottingham 2008,2017

Breast cancer Treatment and Management :Healthcare Education Services:

London Dec 2008,9,10,11,12,13

National Oncoplastic Fellows meeting: Liverpool June 2004,05,06,07,08,10,14,16,17,18

Life Cell Strattice Symposium for Surgeons, Coventry, Bristol, London, Amsterdam, Valencia, Berlin, Aarhus, Tenerife, Rome. Throughout 2010-Present

I have presented and demonstrated both operative and cadaveric Surgical dissection to over 1000 Consultants in this European wide Symposia sponsored by Lifecell/Allergan

I received Professional fees for these meetings

Acelity™ Education Forum Rome 2014, Madrid 2015,Berlin 2016

Home Life

I am married to Celine and have two adult sons. I enjoy scuba diving, skiing, walking in Andalusia and follow my local football team Bolton Wanderers.



1.12.2019

Rick Linforth